$EYEN
EYENOVIA, INC.

2018 Q1 Form 10-K Financial Statement

#000114420418018682 Filed on April 02, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2016 Q4 2016
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.340M $180.0K $570.0K
YoY Change 570.0% -61.74%
% of Gross Profit
Research & Development $2.094M $980.0K $2.966M
YoY Change 129.91% 7.08%
% of Gross Profit
Depreciation & Amortization $5.325K $0.00 $12.80K
YoY Change -23.84% 28.02%
% of Gross Profit
Operating Expenses $3.432M $1.160M $3.535M
YoY Change 210.06% -17.21%
Operating Profit -$3.432M -$3.535M
YoY Change 210.06%
Interest Expense $2.137K $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.430M -$1.160M -$3.530M
YoY Change 209.01% -17.33%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.430M -$1.160M -$3.533M
YoY Change 209.99% -17.25%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$453.7K -$116.7K -$355.1K
COMMON SHARES
Basic Shares Outstanding 9.937M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2016 Q4 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.60M $3.390M
YoY Change 36.14%
Cash & Equivalents $27.60M $3.387M
Short-Term Investments
Other Short-Term Assets $360.0K $0.00
YoY Change -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $27.96M $3.390M $3.390M
YoY Change 20.64%
LONG-TERM ASSETS
Property, Plant & Equipment $22.64K $43.19K $40.00K
YoY Change 300.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $22.64K $43.19K $40.00K
YoY Change 300.0%
TOTAL ASSETS
Total Short-Term Assets $27.96M $3.390M $3.390M
Total Long-Term Assets $22.64K $43.19K $40.00K
Total Assets $27.98M $3.433M $3.430M
YoY Change 21.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $549.1K $302.0K $300.0K
YoY Change 20.0%
Accrued Expenses $540.0K $120.0K
YoY Change -25.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.123M $423.7K $420.0K
YoY Change 0.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.123M $423.7K $420.0K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.120M $420.0K
YoY Change 0.0%
SHAREHOLDERS EQUITY
Retained Earnings -$22.69M -$14.13M
YoY Change
Common Stock $994.00 $227.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.86M $3.009M $3.010M
YoY Change
Total Liabilities & Shareholders Equity $27.98M $3.433M $3.430M
YoY Change 21.63%

Cashflow Statement

Concept 2018 Q1 2016 Q4 2016
OPERATING ACTIVITIES
Net Income -$3.430M -$1.160M -$3.533M
YoY Change 209.99% -17.25%
Depreciation, Depletion And Amortization $5.325K $0.00 $12.80K
YoY Change -23.84% 28.02%
Cash From Operating Activities -$2.391M -$930.0K -$3.204M
YoY Change 175.18% -16.36%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$40.00K $43.12K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$40.00K -$43.12K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $25.09M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.74M 100.0K $4.141M
YoY Change -17.17%
NET CHANGE
Cash From Operating Activities -2.391M -930.0K -$3.204M
Cash From Investing Activities $0.00 -40.00K -$43.12K
Cash From Financing Activities 24.74M 100.0K $4.141M
Net Change In Cash 22.35M -870.0K $894.7K
YoY Change -2636.83% -23.53%
FREE CASH FLOW
Cash From Operating Activities -$2.391M -$930.0K -$3.204M
Capital Expenditures $0.00 -$40.00K $43.12K
Free Cash Flow -$2.391M -$890.0K -$3.247M
YoY Change 171.35% -15.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Entity Registrant Name
EntityRegistrantName
EYENOVIA, INC.
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001682639
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q2 dei Entity Public Float
EntityPublicFloat
51000000 USD
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9936771 shares
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3816732 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2966165 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1315635 USD
CY2017 dei Trading Symbol
TradingSymbol
EYEN
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
568775 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
5132367 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
3534940 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-5132367 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-3534940 USD
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
2380 USD
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
1497 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-5129987 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-3533443 USD
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.19
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2344712 shares
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2266667 shares
CY2017Q4 us-gaap Cash
Cash
5249511 USD
CY2016Q4 us-gaap Cash
Cash
3387288 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
37149 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2335 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27960 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43192 USD
CY2017Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
328700 USD
CY2016Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
246384 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
302031 USD
CY2017Q4 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
306263 USD
CY2016Q4 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
121703 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
552647 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
423734 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
5286660 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
3389623 USD
CY2017Q4 us-gaap Assets
Assets
5643320 USD
CY2016Q4 us-gaap Assets
Assets
3432815 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24351138 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
17139651 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19261186 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14131199 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
5090673 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
3009081 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5643320 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3432815 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
257 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
227 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
36000000 shares
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2566530 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2266667 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2566530 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2266667 shares
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
431574 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
412312 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2690 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
74979 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
2398496 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25466 USD
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12802 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
412312 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2690 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-55647 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
55509 USD
CY2017 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
51560 USD
CY2016 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-51598 USD
CY2017 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
431574 USD
CY2016 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1862223 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
894677 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3387288 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2492611 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5249511 USD
CY2017 eyen Accrual Initial Public Offering Costs
AccrualInitialPublicOfferingCosts
133000 USD
CY2016 eyen Accrual Initial Public Offering Costs
AccrualInitialPublicOfferingCosts
0 USD
CY2017 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
30 USD
CY2016 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4731110 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3203542 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6603567 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4141338 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
34814 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-310498 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43119 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10234 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10234 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43119 USD
CY2017Q4 eyen Working Capital Amount
WorkingCapitalAmount
4734013 USD
CY2017Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4999511 USD
CY2016Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3137288 USD
CY2017Q4 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
28932 USD
CY2016Q4 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
0 USD
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
383 USD
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2335 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
64745 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
47019 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21553 USD
CY2017Q4 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
120455 USD
CY2016Q4 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
61000 USD
CY2017Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
0 USD
CY2016Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
18590 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
41831 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
0 USD
CY2017Q4 eyen Accrued Offering Costs
AccruedOfferingCosts
133000 USD
CY2016Q4 eyen Accrued Offering Costs
AccruedOfferingCosts
0 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10977 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4516 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
33108 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
33108 USD
CY2016Q3 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
3895 USD
CY2016Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-09-14
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
45678 USD
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
18590 USD
CY2017 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P2Y
CY2017Q4 eyen Minority Interest Ownership Percentage In Company
MinorityInterestOwnershipPercentageInCompany
0.05 pure
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
235473 USD
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
1287931 USD
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
80301 USD
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
151521 USD
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
315774 USD
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1439452 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.063 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.027 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.062 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.407 pure
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0 pure
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0 pure
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2588641 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2742397 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
347977 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
333066 USD
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
526134 USD
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
201840 USD
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
364508 USD
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
234183 USD
CY2017 eyen Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Life
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife
P9Y8M12D
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3827260 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3511486 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3827260 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3511486 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
61875 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
61875 shares
CY2017 eyen Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercisable Number
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber
61875 shares
CY2017 eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice
6.98
CY2017 eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice
0
CY2017 eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice
6.98
CY2016Q4 eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice
0
CY2017Q4 eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice
6.98
CY2017 eyen Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Remaining Contractual Terms
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms
P9Y8M12D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P9Y8M12D
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0 USD
CY2017 eyen Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercisable Aggregated Intrinsic Vallue
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue
0 USD
CY2017 eyen Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Warrants
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants
61875 shares
CY2017 eyen Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Warrants
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants
61875 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.31 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0195 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0239 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0153 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0183 pure
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
786669 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
897747 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1684416 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
920383 shares
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.95
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.37
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.68
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.39
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
883675 USD
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1684416 shares
CY2017 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
920383 shares
CY2017Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
61875 shares
CY2017Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.98
CY2017Q3 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
431574 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.77
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.16
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
412312 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
2690 USD
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1327224 USD
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4141338 USD
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6367693 USD
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2017 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
195700 USD
CY2016 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
0 USD
CY2017 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Florida
CY2017 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-03-12
CY2017 us-gaap Tax Credit Carryforward Limitations On Use
TaxCreditCarryforwardLimitationsOnUse
In accordance with Section 382 of the Internal Revenue Code, the usage of the Company's net operating loss carry forwards could become subject to annual limitations if there are greater than 50% ownership changes.
CY2017 eyen Proceeds Of Stock Issued During Period Gross
ProceedsOfStockIssuedDuringPeriodGross
6409651 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
41958 USD
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> establishment of</font> valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company&#8217;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company&#8217;s estimates and could cause actual results to differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Summary of Significant Accounting Policies&#160;&#151; Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&#8217;s common stock.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6386532 shares
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4807787 shares
CY2017Q4 eyen Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
0 USD
CY2016Q4 eyen Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
37597 USD
CY2017Q4 eyen Accrued Expenses And Other Liabilities Currents
AccruedExpensesAndOtherLiabilitiesCurrents
306263 USD
CY2016Q4 eyen Accrued Expenses And Other Liabilities Currents
AccruedExpensesAndOtherLiabilitiesCurrents
121703 USD
CY2016 eyen Income Tax Expense Benefit Before Adjustments For Change In Valuation Allowance
IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance
1439452 USD
CY2017 eyen Income Tax Expense Benefit Before Adjustments For Change In Valuation Allowance
IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance
315774 USD
CY2017 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
1100000 USD
CY2017 us-gaap Malpractice Loss Contingency Insurance Recoveries
MalpracticeLossContingencyInsuranceRecoveries
10000000 USD
CY2016Q3 us-gaap Net Rentable Area
NetRentableArea
953 acre
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4361825 USD
CY2016Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
7200000 USD
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
1500000 USD
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1500000 USD
CY2015 eyen Related Parties Ownership Interest Percentage
RelatedPartiesOwnershipInterestPercentage
0.05 pure
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2017Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
328700 USD
CY2016Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 USD
CY2017Q1 us-gaap Share Price
SharePrice
3.23
CY2017Q1 us-gaap Fair Value Inputs Discount For Lack Of Marketability
FairValueInputsDiscountForLackOfMarketability
0.4 pure
CY2017Q1 eyen Share Price At Fair Value
SharePriceAtFairValue
1.95
CY2017Q4 eyen Prepaid Patent Expense
PrepaidPatentExpense
7833 USD
CY2017 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.081 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.0 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.30 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0 pure
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
11000000 USD
CY2017 eyen Operating Loss Carryforwards Expiration Term
OperatingLossCarryforwardsExpirationTerm
2034 to 2037
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 eyen Preferred Stock Prorata Allotment Pecentage
PreferredStockProrataAllotmentPecentage
0.75 pure
CY2017 eyen Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum
P5Y3M25D
CY2017 eyen Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum
P10Y

Files In Submission

Name View Source Status
0001144204-18-018682-index-headers.html Edgar Link pending
0001144204-18-018682-index.html Edgar Link pending
0001144204-18-018682.txt Edgar Link pending
0001144204-18-018682-xbrl.zip Edgar Link pending
eyen-20171231.xml Edgar Link completed
eyen-20171231.xsd Edgar Link pending
eyen-20171231_cal.xml Edgar Link unprocessable
eyen-20171231_def.xml Edgar Link unprocessable
eyen-20171231_lab.xml Edgar Link unprocessable
eyen-20171231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv488528_10k.htm Edgar Link pending
tv488528_ex31-1.htm Edgar Link pending
tv488528_ex31-2.htm Edgar Link pending
tv488528_ex32-1.htm Edgar Link pending
tv488528_ex32-2.htm Edgar Link pending
tv488528_img1.jpg Edgar Link pending
tv488528_img10.jpg Edgar Link pending
tv488528_img11.jpg Edgar Link pending
tv488528_img2.jpg Edgar Link pending
tv488528_img3.jpg Edgar Link pending
tv488528_img4.jpg Edgar Link pending
tv488528_img5.jpg Edgar Link pending
tv488528_img6.jpg Edgar Link pending
tv488528_img7.jpg Edgar Link pending
tv488528_img8.jpg Edgar Link pending
tv488528_img9.jpg Edgar Link pending